Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Operating Leases (2019 - 2025)

Heron Therapeutics' Operating Leases history spans 7 years, with the latest figure at $780000.0 for Q3 2025.

  • For Q3 2025, Operating Leases rose 49.43% year-over-year to $780000.0; the TTM value through Sep 2025 reached $780000.0, up 49.43%, while the annual FY2023 figure was $2.8 million, 49.08% down from the prior year.
  • Operating Leases reached $780000.0 in Q3 2025 per HRTX's latest filing, down from $1.5 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $13.8 million in Q1 2021 to a low of $522000.0 in Q3 2024.
  • Average Operating Leases over 5 years is $5.5 million, with a median of $4.8 million recorded in 2023.
  • Peak YoY movement for Operating Leases: tumbled 85.24% in 2024, then skyrocketed 49.43% in 2025.
  • A 5-year view of Operating Leases shows it stood at $8.0 million in 2021, then crashed by 31.23% to $5.5 million in 2022, then plummeted by 49.08% to $2.8 million in 2023, then tumbled by 81.36% to $522000.0 in 2024, then surged by 49.43% to $780000.0 in 2025.
  • Per Business Quant, the three most recent readings for HRTX's Operating Leases are $780000.0 (Q3 2025), $1.5 million (Q2 2025), and $522000.0 (Q3 2024).